These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Oral lichenoid reactions during antimalarial prophylaxis with sulphadoxine-pyrimethamine combination. Zain RB Southeast Asian J Trop Med Public Health; 1989 Jun; 20(2):253-6. PubMed ID: 2609215 [TBL] [Abstract][Full Text] [Related]
47. Does chloroquine contribute to the risk of serious adverse reactions to fansidar? Rombo L; Stenbeck J; Lobel HO; Campbell CC; Papaioanou M; Miller KD Lancet; 1985 Dec; 2(8467):1298-9. PubMed ID: 2866354 [No Abstract] [Full Text] [Related]
48. Leads from the MMWR. Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria. JAMA; 1985 Jan; 253(4):483. PubMed ID: 3881605 [No Abstract] [Full Text] [Related]
49. [The risks of pyrimethamine-sulfadoxine combination in the prenatal treatment of toxoplasmosis]. Dorangeon PH; Marx-Chemla C; Quereux C; Fay R; Leroux B; Choisy H; Pinon JM; Wahl P J Gynecol Obstet Biol Reprod (Paris); 1992; 21(5):549-56. PubMed ID: 1401771 [TBL] [Abstract][Full Text] [Related]
51. Boxed warning added to Fansidar labeling. FDA Drug Bull; 1985 Aug; 15(2):21. PubMed ID: 4054454 [No Abstract] [Full Text] [Related]
52. [Drug-induced exudative erythema multiforme major with a chronic progressive course and bilateral blindness. Clinical and immunohistologic follow-up]. Thiel HJ; Richter U; Pleyer U; Zierhut M; Steuhl KP Klin Monbl Augenheilkd; 1990 Aug; 197(2):142-9. PubMed ID: 2147046 [TBL] [Abstract][Full Text] [Related]
53. Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. Pearson RD; Hewlett EL Ann Intern Med; 1987 May; 106(5):714-8. PubMed ID: 3551713 [TBL] [Abstract][Full Text] [Related]
54. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Hernborg A Lancet; 1985 Nov; 2(8463):1072-3. PubMed ID: 2865554 [No Abstract] [Full Text] [Related]
55. The safety of pyrimethamine and sulfadoxine for the prevention of Pneumocystis carinii pneumonia. Teira R; Virosta M; Muñoz J; Zubero Z; Santamaría JM Scand J Infect Dis; 1997; 29(6):595-6. PubMed ID: 9580544 [TBL] [Abstract][Full Text] [Related]
56. Fansidar-associated fatal reaction in an HIV-infected man. Centers for Disease Control (CDC) MMWR Morb Mortal Wkly Rep; 1988 Sep; 37(37):571-2, 577. PubMed ID: 3137443 [No Abstract] [Full Text] [Related]
57. Presumptive fatality due to pyrimethamine-sulfadoxine. Whitfield D Lancet; 1982 Dec; 2(8310):1272. PubMed ID: 6128564 [No Abstract] [Full Text] [Related]
58. Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug. Fairhurst RM; Sadou B; Guindo A; Diallo DA; Doumbo OK; Wellems TE Trans R Soc Trop Med Hyg; 2003; 97(5):595-6. PubMed ID: 15307435 [TBL] [Abstract][Full Text] [Related]
59. Investigation of Four Cases of Stevens-Johnson Syndrome among Participants in a Mass Drug Administration Campaign with Sulfadoxine-Pyrimethamine and Primaquine in Haiti, 2020. Chang MA; Fouché B; LaFortune W; Holmes K; Rigodon J; Juin S; Marseille S; Rogier E; Green M; Kheradmand T; Moore SG; Gaul DA; Boncy J; Telfort MA Am J Trop Med Hyg; 2023 Jun; 108(6):1140-1144. PubMed ID: 37127264 [TBL] [Abstract][Full Text] [Related]
60. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Peters PJ; Thigpen MC; Parise ME; Newman RD Drug Saf; 2007; 30(6):481-501. PubMed ID: 17536875 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]